You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NextGen Sciences, Berg Diagnostics
Neal Siegel, Glenn Barney, Hiroshi Saito, Jay Moyes, Michael Marletta, Richard Lerner
In about a month, the company plans to offer four assays targeted to neurodegenerative disease and heart disease, its CEO said.
The assays will be used by the drug company for preclinical and clinical studies.
Thermo Fisher's BRIMS Center is collaborating with NextGen Sciences to improve that company's suite of biomarker services.
The sale, for undisclosed cash and royalties, completes NextGen's realignment toward biomarker services.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.